title: A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?
authors.forename: M K
authors.initials: MK
authors.lastname: Reinders
authors.forename: E N
authors.initials: EN
authors.lastname: van Roon
authors.forename: J R B J
authors.initials: JR
authors.lastname: Brouwers
authors.forename: T L Th A
authors.initials: TL
authors.lastname: Jansen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015210:Arthritis, Gouty / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007231:Infant, Newborn; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D014503:Urate Oxidase / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; C469709:rasburicase; D014503:Urate Oxidase; D000068800:Etanercept